Patient, Consumer Groups Decry Lack Of User Fee Funding For Post-Market Surveillance
This article was originally published in The Gray Sheet
Executive Summary
Non-industry stakeholders criticized the medical device user fee agreement for not giving FDA enough funding, particularly to enhance post-market surveillance programs, during an FDA public meeting on user fee reauthorization.
You may also be interested in...
Senate Plans FDA User Fee Markup This Week; House Not Far Behind
Updated draft user fee reauthorization bills issued last week reflect works in progress as lawmakers aim to reach consensus on FDA reforms.
Draft User Fee Bills Aim To Streamline And Strengthen Device Regs
Details on draft legislation circulating in the House and Senate.
FDA Sets March 28 Date To Discuss Newly Published Draft User Fee Pact
The agency published its draft commitment letter and draft legislative language for user fee reauthorization March 15. A public meeting is set for the end of the month, and public comments will be accepted through April 16.